Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Slides:

Advertisements

Similar presentations

Volume 56, Issue 5, Pages (November 2009)

Advertisements

Volume 72, Issue 1, Pages (July 2017)

Volume 155, Issue 3, Pages (March 1996)

Volume 50, Issue 3, Pages (September 2006)

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 2, Pages (August 2015)

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 71, Issue 1, Pages (January 2017)

Volume 49, Issue 2, Pages (February 2006)

Volume 66, Issue 4, Pages (October 2014)

Volume 73, Issue 6, Pages (June 2018)

Volume 64, Issue 4, Pages (October 2013)

Volume 51, Issue 4, Pages (April 2007)

Volume 52, Issue 3, Pages (September 2007)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 60, Issue 5, Pages (November 2011)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 56, Issue 2, Pages (August 2009)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Counselling the Prostate Cancer Patient

Volume 63, Issue 6, Pages (June 2013)

Volume 66, Issue 6, Pages (December 2014)

Luis Martínez-Piñeiro European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 66, Issue 2, Pages (August 2014)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Volume 71, Issue 1, Pages (January 2017)

Volume 65, Issue 6, Pages (June 2014)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 58, Issue 1, Pages (July 2010)

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Volume 72, Issue 4, Pages (October 2017)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

PSA Levels and the Probability of Prostate Cancer on Biopsy

Volume 59, Issue 4, Pages (April 2011)

Volume 72, Issue 1, Pages (July 2017)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Prostate Cancer 2008: Challenges in Diagnosis and Management

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 54, Issue 5, Pages (November 2008)

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 74, Issue 6, Pages (December 2018)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Serum Markers for Prostate Cancer: A Rational Approach to the Literature Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology Volume 54, Issue 1, Pages 31-40 (July 2008) DOI: 10.1016/j.eururo.2008.01.034 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Predicted probability of a prostate cancer diagnosis before age 75 years by population-based centiles of prostate-specific antigen (PSA) measured at age 44 to 50 years, with 95% CI. From Lilja et al [15]. European Urology 2008 54, 31-40DOI: (10.1016/j.eururo.2008.01.034) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Diagnostic accuracy (AUC) of a “base” model to predict biopsy outcome including age and pre-treatment total PSA and of the same model supplemented by free PSA subforms and various plasminogen activator receptor (uPAR) isoforms (full model) among 355 referral patients. European Urology 2008 54, 31-40DOI: (10.1016/j.eururo.2008.01.034) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Serum analysis of EPCA-2 in a total of 330 serum samples screened for EPCA-2.22. Indirect ELISAs showed that EPCA-2.22 has cutoff of 30ng/ml or greater at estimated concentration. Cutoff represented by the orange line across the graph. From Leman et al. [56]. European Urology 2008 54, 31-40DOI: (10.1016/j.eururo.2008.01.034) Copyright © 2008 European Association of Urology Terms and Conditions